ES3067370T3 - Method for treating cough by using diaminopyrimidine compound - Google Patents

Method for treating cough by using diaminopyrimidine compound

Info

Publication number
ES3067370T3
ES3067370T3 ES20799419T ES20799419T ES3067370T3 ES 3067370 T3 ES3067370 T3 ES 3067370T3 ES 20799419 T ES20799419 T ES 20799419T ES 20799419 T ES20799419 T ES 20799419T ES 3067370 T3 ES3067370 T3 ES 3067370T3
Authority
ES
Spain
Prior art keywords
approximately
days
compound
cough
saturated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES20799419T
Other languages
English (en)
Spanish (es)
Inventor
Yanping Zhao
Hongjun Wang
Huai Huang
Yuanyuan Jiang
Huining Liang
Ran An
Zhou Lan
Jin Wang
Liying Zhou
Yanan Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Tide Pharmaceutical Co Ltd
Original Assignee
Beijing Tide Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Tide Pharmaceutical Co Ltd filed Critical Beijing Tide Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES3067370T3 publication Critical patent/ES3067370T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES20799419T 2019-04-30 2020-04-29 Method for treating cough by using diaminopyrimidine compound Active ES3067370T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019085180 2019-04-30
PCT/CN2020/087686 WO2020221274A1 (zh) 2019-04-30 2020-04-29 二氨基嘧啶类化合物治疗咳嗽的方法

Publications (1)

Publication Number Publication Date
ES3067370T3 true ES3067370T3 (en) 2026-05-21

Family

ID=73029672

Family Applications (1)

Application Number Title Priority Date Filing Date
ES20799419T Active ES3067370T3 (en) 2019-04-30 2020-04-29 Method for treating cough by using diaminopyrimidine compound

Country Status (12)

Country Link
US (1) US20220211703A1 (cg-RX-API-DMAC7.html)
EP (1) EP3960179B1 (cg-RX-API-DMAC7.html)
JP (1) JP7665529B2 (cg-RX-API-DMAC7.html)
KR (1) KR102935436B1 (cg-RX-API-DMAC7.html)
CN (1) CN114007619B (cg-RX-API-DMAC7.html)
AU (1) AU2020265327B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021021600A2 (cg-RX-API-DMAC7.html)
ES (1) ES3067370T3 (cg-RX-API-DMAC7.html)
MX (1) MX2021013338A (cg-RX-API-DMAC7.html)
SG (1) SG11202111877TA (cg-RX-API-DMAC7.html)
TW (1) TWI736243B (cg-RX-API-DMAC7.html)
WO (1) WO2020221274A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117186068A (zh) * 2017-11-01 2023-12-08 北京泰德制药股份有限公司 P2x3和/或p2x2/3受体拮抗剂、包含其的药物组合物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1725540E (pt) * 2004-03-05 2012-11-29 Hoffmann La Roche Diaminopirimidinas como antagonistas de p2x3 e p2x2/3
ES2612890T3 (es) * 2005-09-01 2017-05-19 F. Hoffmann-La Roche Ag Diaminopirimidinas como moduladores de P2X3 y P2X2/3
DK2343281T3 (en) 2006-10-04 2014-03-24 Hoffmann La Roche Process for the Synthesis of Phenoxydiamino-Pyrimidine Derivatives
PE20160431A1 (es) * 2013-08-23 2016-06-02 Afferent Pharmaceuticals Inc Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o cronica
CA2998742C (en) * 2015-09-29 2023-08-29 Anthony P. FORD Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough
US10822311B2 (en) * 2016-03-14 2020-11-03 Afferent Pharmaceuticals, Inc. Pyrimidines and variants thereof, and uses therefor
AU2017237929B2 (en) * 2016-03-25 2021-04-15 Afferent Pharmaceuticals Inc. Pyrimidines and variants thereof, and uses therefor
CN117186068A (zh) * 2017-11-01 2023-12-08 北京泰德制药股份有限公司 P2x3和/或p2x2/3受体拮抗剂、包含其的药物组合物及其用途

Also Published As

Publication number Publication date
JP7665529B2 (ja) 2025-04-21
JP2022530890A (ja) 2022-07-04
KR102935436B1 (ko) 2026-03-05
SG11202111877TA (en) 2021-11-29
MX2021013338A (es) 2022-01-24
BR112021021600A2 (pt) 2022-01-04
TWI736243B (zh) 2021-08-11
EP3960179A1 (en) 2022-03-02
KR20220007620A (ko) 2022-01-18
US20220211703A1 (en) 2022-07-07
AU2020265327A1 (en) 2021-12-16
CN114007619B (zh) 2024-08-06
EP3960179B1 (en) 2026-03-18
CN114007619A (zh) 2022-02-01
TW202106302A (zh) 2021-02-16
EP3960179A4 (en) 2023-01-25
CA3138780A1 (en) 2020-11-05
AU2020265327B2 (en) 2025-09-11
WO2020221274A1 (zh) 2020-11-05